Suchergebnisse - "O'Day, Steven J"

PubPharm (117)

11

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2015

von Ribas, A. | Puzanov, I. | Dummer, R. | +33

CommentIn: Lancet Oncol. 2015 Aug;16(8):873-4. - PMID 26115798

12

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Carvajal, R. | Lawrence, D. | Weber, J. | +17

13

Clinical cancer advances 2015 : Annual report on progress against cancer from the American Society of Clinical Oncology

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2015

von Masters, G. | Krilov, L. | Bailey, H. | +16

14

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

enthalten in: Journal of translational medicine | 2015

von Dummer, R. | Daud, A. | Puzanov, I. | +18

15

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

enthalten in: Journal of translational medicine | 2015

von Dummer, R. | Daud, A. | Puzanov, I. | +18

16

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2015

von Masters, G. | Krilov, L. | Bailey, H. | +16

17

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

enthalten in: Clinical cancer research | 2015

von Carvajal, R. | Lawrence, D. | Weber, J. | +17

18

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

enthalten in: The lancet / Oncology | 2015

von Ribas, A. | Puzanov, I. | Dummer, R. | +33

19

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2014

von Falchook, G. | Long, G. | Kurzrock, R. | +15

20

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

enthalten in: Clinical cancer research | 2014

von Falchook, G. | Long, G. | Kurzrock, R. | +15